Alan Brochstein

Tiny Accentia Biopharmaceuticals May Be On Its Way To Big Things

Sorry, Fred, but ABPI is dead...

Cancer Stocks Hammered Once Again

I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot.

Tiny Accentia Biopharmaceuticals May Be On Its Way To Big Things

Yes, I first came to know ABPI through PPDI. Trust me, they make investment mistakes - review their 10-Ks over the past few years and you will see lots of write-downs of investments such as ABPI. I wouldn't put too much into what the analyst says regarding the Sinunase potential for PPDI. I also would say that of course PPDI talks it up (at least for now). They have had failures in their compound partnering strategy - this won't be the first.

Like I said, I took the medicine, and it wasn't fun at all - they need a different delivery mechanism. Millions of people take Flonase or other types of suspensions - very tolerable. This is like an enema for the nose - not fun....

Even with FDA approval, which may not happen, the company will have a tough time on the reimbursement front in my opinion. I am sure that ABPI has lots of experience in that area - not!

By the way, this is the slowest "fast track" I have ever seen...

Tiny Accentia Biopharmaceuticals May Be On Its Way To Big Things

I beg to differ, but this one looks like it will be gone soon. I believe that one can already get "Sinunase" from a compounding pharmacy (ampotericin B + H20). I tried it and found it very unpleasant. I wonder if it will even get FDA approval. Call me a skeptic, but this company is short on cash and long on disappointment.

Cancer Stocks Hammered Once Again

Thanks for the comment and the compliment. Thanks also for the information. Contact me by phone or email if you would like to discuss your ideas.

Cancer Stocks Slide Again

I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine).

Cancer Stocks Plunge Following ASCO Meeting

Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming the stock market, generating losses and diluting with equity issuance. That isn't to say that one might find a diamond in the garbage can, but, I think that one is actually more likely to find a diamond in the garbage can. If one of these companies is creating a truly novel, revolutionary treatment, I personally believe that an investor would have plenty of time to buy later at a higher price and still make a ton of money.

Note, I don't have an opinion specifically on Insmed other than my general observations in the above paragraph.

Cancer Stocks on the Go: Winners and Losers

You get what you pay for, then. If I could publish this list in advance, well, I would be doing it from my boat in the Bahamas!

Many investors look at price action in order to alert them to areas where they should be focused. Is the move overdone (take profits), or is it sustainable (consider buying).